Australia's INOVIQ eyes best day in over 2 yrs on upbeat cancer test results

Inoviq

27/06/2023 04:32

** Shares of medical diagnostics firm INOVIQ  IIQ.AX  surge
as much as 50% to A$0.75; on track for best session since Feb.
16, 2021, if gains hold
    ** Co posts results from an independent clinical validation
study of its SubB2M/CA15-3 test for breast cancer detection
    ** Says study showed 87% high accuracy, 81% sensitivity and
93% specificity for the SubB2M test, outperforming a leading
approved CA15-3 test
    ** Adds it is finalising its planned breast cancer
monitoring study and advancing discussions with potential
partners and key opinion leaders for its SubB2M platform and
tests
    ** Stock hits highest level since Dec. 13, 2022
    ** Over 1.3 mln shares have changed hands, vs the 30-day
average of ~67,000 shares 
    ** As of last close, IIQ stock down ~21.9% YTD
    


 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))